Company profile: Cerus Endovascular
1.1 - Company Overview
Company description
- Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cerus Endovascular
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for immunologic, immuno-oncologic and rare genetic disorders, advancing treatments for rare and orphan diseases. Pipeline includes AVTX-009 (anti-IL-1β) for inflammatory diseases; quisovalimab (anti-LIGHT) for inflammatory conditions; AVTX-008 (BTLA agonist) for immune dysregulation; and AVTX-002 (anti-LIGHT) in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
Convelo Therapeutics
HQ: United States
Website
- Description: Provider of novel remyelinating therapeutics that regenerate myelin in the central nervous system to restore function, supported by a proprietary screening platform that identifies candidates acting on oligodendrocyte progenitor cells, and a collaboration with Genentech to accelerate discovery and development of medicines for neurological disorders such as multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convelo Therapeutics company profile →
BioDelivery Sciences International
HQ: United States
Website
- Description: Provider of pharmaceutical solutions focused on pain management and addiction medicine, leveraging proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize new applications of proven therapies independently or through partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDelivery Sciences International company profile →
AlzProtect
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates and clinical development for neurodegenerative diseases, including Alzheimer’s disease and orphan tauopathies such as Progressive Supranuclear Palsy. Offers AZP2006 with a unique mechanism targeting amyloid toxicity, Tau phosphorylation, oxidative stress, and neuroinflammation; conducts clinical trials and partners with pharmaceutical companies for marketing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AlzProtect company profile →
Trevena
HQ: United States
Website
- Description: Provider of an approved intravenous opioid analgesic (OLINVYK) for the management of acute pain in adults when alternative treatments are inadequate, and developer of GPCR-biased ligands, including TRV045 (oral S1P receptor; diabetic neuropathic pain and epilepsy; Phase 1), TRV250 (delta receptor; acute migraine; Phase 1), and TRV734 (oral mu receptor; maintenance treatment of opioid use disorder; Phase 1).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trevena company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cerus Endovascular
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cerus Endovascular
2.2 - Growth funds investing in similar companies to Cerus Endovascular
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cerus Endovascular
4.2 - Public trading comparable groups for Cerus Endovascular
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →